Overview

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Status:
Enrolling by invitation

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls and women with Rett syndrome

Phase:

Phase 3

Details

Lead Sponsor:

ACADIA Pharmaceuticals Inc.